ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
62,506.62
0.28%
S&P 500
5,189.60
0.04%
Dow Jones
38,965.04
0.21%
US Dollar vs Yen
155.571
0.53%
Brent Oil
83.105
0.29%
Registration Strip Icon for discussion 登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Sanofi (SNY)

  7. Sanofi (SNY) ニュース

SNY

Sanofi (SNY)

Sanofi
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:SNY
日付受信時刻ニュースソース見出しコード企業名
2024/04/2520 : 52IH Market NewsSouthwest Shares Tumble 9.6% Post $231 Million 1Q Loss, AstraZeneca Surges on 19% Annual Increase, and More on EarningsNASDAQ:SNYSanofi
2024/04/1920 : 31IH Market NewsParamount’s Shares Surge Following Sony and Apollo’s Joint Bid; ISS Backs Berkshire Hathaway Director Re-election, and MoreNASDAQ:SNYSanofi
2024/02/2404 : 02Edgar (US Regulatory)Form IRANNOTICE - Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 (Exchange Act Section 13(r)).NASDAQ:SNYSanofi
2024/02/2401 : 15Edgar (US Regulatory)Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]NASDAQ:SNYSanofi
2024/02/1602 : 09Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SNYSanofi
2024/02/1505 : 57Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:SNYSanofi
2024/01/2604 : 29GlobeNewswire Inc.Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE)NASDAQ:SNYSanofi
2024/01/2321 : 23Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SNYSanofi
2024/01/2320 : 05Dow Jones NewsSanofi to Buy Assets From Inhibrx in Deal Valued at Up to $2.2 Billion -- UpdateNASDAQ:SNYSanofi
2024/01/2319 : 40IH Market NewsWall Street Highlights: Vroom Shuts Down Online Car Sales, Ericsson Warns of Decline Outside China, and MoreNASDAQ:SNYSanofi
2024/01/2315 : 00PR Newswire (US)Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2BNASDAQ:SNYSanofi
2024/01/1803 : 49Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SNYSanofi
2024/01/0916 : 14Dow Jones NewsSanofi Names Brian Foard Head of Specialty-Care UnitNASDAQ:SNYSanofi
2023/12/2801 : 18Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SNYSanofi
2023/12/2116 : 25Dow Jones NewsSanofi Ends Drug Program After Late-Stage Trial in Lung Cancer FailsNASDAQ:SNYSanofi
2023/12/1921 : 28Dow Jones NewsInnate Pharma Shares Rise after Sanofi Exercises Licensing OptionNASDAQ:SNYSanofi
2023/12/1219 : 50IH Market NewsHasbro Job Cuts, Oracle’s Stock Decline, Google’s Epic Antitrust Loss, and MoreNASDAQ:SNYSanofi
2023/12/1207 : 18Dow Jones NewsSanofi Terminates Agreement with Maze Therapeutics Following FTC OppositionNASDAQ:SNYSanofi
2023/12/1115 : 50Dow Jones NewsSanofi Sees Improvement in Trial Results of Cancer Drug SarclisaNASDAQ:SNYSanofi
2023/12/0716 : 34Dow Jones NewsSanofi Myeloma Drug Sarclisa Met Primary Goal in Late-Stage TrialNASDAQ:SNYSanofi
2023/12/0716 : 20Dow Jones NewsSanofi Sees Annual Sales From New Pharma Assets Above $10.8 Billion by 2030NASDAQ:SNYSanofi
2023/12/0622 : 20Dow Jones NewsTrending: Merck's Multiple Sclerosis Drug Misses Expectations in Late-Stage TrialsNASDAQ:SNYSanofi
2023/12/0619 : 14Dow Jones NewsMerck Shares Slump After Multiple Sclerosis Drug Fails in Late-Stage TrialsNASDAQ:SNYSanofi
2023/11/3023 : 23Dow Jones NewsTeva Closes Collaboration Deal With Sanofi on IBD TreatmentNASDAQ:SNYSanofi
2023/11/3022 : 30Business WireTeva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease TreatmentNASDAQ:SNYSanofi
2023/11/2800 : 31Dow Jones NewsTrending: Sanofi's Notus Trial Meets Primary EndpointNASDAQ:SNYSanofi
2023/11/2716 : 40Dow Jones NewsSanofi Says Notus Phase 3 Trial of Dupixent Met Primary EndpointNASDAQ:SNYSanofi
2023/11/2715 : 30GlobeNewswire Inc.Dupixent® (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious DiseaseNASDAQ:SNYSanofi
2023/11/0806 : 01AllPennyStocks.comOrphan Drugs Worth $64 Billion by 2028 and This Micro Cap Could Have One by That TimeNASDAQ:SNYSanofi
2023/11/0722 : 56Dow Jones NewsSanofi Under Preliminary Probe in France Over Possible Market Manipulation, Source SaysNASDAQ:SNYSanofi
 Showing the most relevant articles for your search:NASDAQ:SNY

最近閲覧した銘柄

CCOM
SILVER
SILVER
USOTC
ADDYY
Adidas (QX)
CCOM
US100
US Tech 100
NYSE
BAC
Bank of America
NASDAQ
AMZN
Amazon.com
PM
XAUUSD
Gold vs US Dollar
NYSE
MCD
McDonalds
USOTC
BASFY
BASF (QX)
NYSE
JPM
JP Morgan Chase
NASDAQ
QQQ
Invesco QQQ Trust Series 1
COIN
BTCUSD
Bitcoin
NASDAQ
AAPL
Apple
NYSE
AXP
American Express
SPI
SP500
S&P 500
AMEX
XLV
Health Care Select Sector
NYSE
VZ
Verizon Communications
Delayed Upgrade Clock
ADVFN Logo

日本
会社情報
ビジネス
人気
アプリを入手

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有